{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:27:53Z","timestamp":1773235673618,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2009,9,12]],"date-time":"2009-09-12T00:00:00Z","timestamp":1252713600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s00520-009-0740-1","type":"journal-article","created":{"date-parts":[[2009,9,11]],"date-time":"2009-09-11T09:41:43Z","timestamp":1252662103000},"page":"1263-1270","source":"Crossref","is-referenced-by-count":5,"title":["Heated (37\u00b0C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?"],"prefix":"10.1007","volume":"18","author":[{"given":"Richard","family":"Cathomas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dieter","family":"K\u00f6berle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Ruhstaller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisela","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"R\u00e4ss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Mey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"von Moos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,9,12]]},"reference":[{"key":"740_CR1","unstructured":"Todesursachenstatistik Schweiz 2001\u20132002 (2005) Bundesamt f\u00fcr Statistik, Neuchatel, Switzerland. www.bfs.admin.ch"},{"key":"740_CR2","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1200\/JCO.2002.07.087","volume":"20","author":"MM Borner","year":"2002","unstructured":"Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, Herrmann R, Pestalozzi BC, Saletti P, Hanselmann S, Muller S, Brauchli P, Castiglione-Gertsch M, Goldhirsch A, Roth AD (2002) Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 20:1759\u20131766","journal-title":"J Clin Oncol"},{"key":"740_CR3","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1200\/JCO.2004.11.069","volume":"22","author":"J Cassidy","year":"2004","unstructured":"Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, Sch\u00f6ffski P, Sobrero A, Van Cutsem E, Diaz-Rubio E (2004) XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22:2084\u20132091","journal-title":"J Clin Oncol"},{"key":"740_CR4","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","volume":"26","author":"J Cassidy","year":"2008","unstructured":"Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera S, Couture F, Sirz\u00e9n F, Saltz L (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006\u20132012","journal-title":"J Clin Oncol"},{"key":"740_CR5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0093-7754(03)00399-3","volume":"30","author":"A Grothey","year":"2003","unstructured":"Grothey A (2003) Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 30:5\u201313","journal-title":"Semin Oncol"},{"key":"740_CR6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/sonc.2002.35525","volume":"29","author":"E Gamelin","year":"2002","unstructured":"Gamelin E, Gamelin L, Bossi L, Quasthoff S (2002) Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 29:21\u201333","journal-title":"Semin Oncol"},{"issue":"Suppl. 1","key":"740_CR7","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.3816\/CCC.2005.s.006","volume":"5","author":"A Grothey","year":"2005","unstructured":"Grothey A (2005) Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer 5(Suppl. 1):S38\u2013S46","journal-title":"Clin Colorectal Cancer"},{"key":"740_CR8","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/annonc\/mdh186","volume":"15","author":"D Elias","year":"2004","unstructured":"Elias D, Sideris L, Pocard M, Ede C, Hassouna D, Ducreux M, Boige V, Cote JF, Lasser P (2004) Efficacy of intraperitoneal chemohyperthermia with oxaliplatin in colorectal peritoneal carcinomatosis. Preliminary results in 24 patients. Ann Oncol 15:781\u2013785","journal-title":"Ann Oncol"},{"key":"740_CR9","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/annonc\/mdf019","volume":"13","author":"D Elias","year":"2002","unstructured":"Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El OA, Pignon JP, Drouard-Troalen L, Ouellet JF, Ducreux M (2002) Heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 13:267\u2013272","journal-title":"Ann Oncol"},{"key":"740_CR10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L, Van Glabbeke M, van Oosterom A, Christian M, Gwyther S (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"740_CR11","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/jnci\/86.21.1608","volume":"86","author":"FA Levi","year":"1994","unstructured":"Levi FA, Zidani R, Vannetzel JM et al (1994) Chronomodulted versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 86:1608\u20131617","journal-title":"J Natl Cancer Inst"},{"key":"740_CR12","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1471-2407-5-116","volume":"5","author":"GD Leonard","year":"2005","unstructured":"Leonard GD, Wright M, Quinn MG, Fioravanti S, Harold N, Schuler B, Thomas RR, Grem JL (2005) Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 5:116","journal-title":"BMC Cancer"},{"key":"740_CR13","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/annonc\/mdm267","volume":"18","author":"H Sorbye","year":"2007","unstructured":"Sorbye H, K\u00f6hne CH, Sargent DJ, Glimelius B (2007) Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification. Ann Oncol 18:1666\u20131672","journal-title":"Ann Oncol"},{"key":"740_CR14","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/annonc\/mdn058","volume":"19","author":"M Borner","year":"2008","unstructured":"Borner M, Koeberle D, Von Moos R, Saletti P, Rauch D, Hess V, Trojan A, Helbling D, Pestalozzi B, Caspar C, Ruhstaller T, Roth A, Kappeler A, Dietrich D, Lanz D, Mingrone W (2008) Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Ann Oncol 19:1288\u20131292","journal-title":"Ann Oncol"},{"key":"740_CR15","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-03-0666","volume":"10","author":"L Gamelin","year":"2004","unstructured":"Gamelin L, Boisdron-Celle M, Delva R, Gu\u00e9rin-Meyer V, Ifrah N, Morel A, Gamelin E (2004) Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10:4055\u20134061","journal-title":"Clin Cancer Res"},{"key":"740_CR16","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1200\/JCO.2007.13.5251","volume":"25","author":"HS Hochster","year":"2007","unstructured":"Hochster HS, Grothey A, Childs BH (2007) Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol 25:4028\u20134029","journal-title":"J Clin Oncol"},{"key":"740_CR17","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2007.15.3767","volume":"26","author":"L Gaemlin","year":"2008","unstructured":"Gaemlin L, Boisdron-Celle M, Morel A, Poirier AL, Berger V, Gamelin E, Tournigand C, de Gramont A (2008) Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol 26:1188\u20131189 author reply 1189\u20131190","journal-title":"J Clin Oncol"},{"key":"740_CR18","doi-asserted-by":"crossref","unstructured":"Grothey A, Hart LL, Rowland KM, Ansari RH, Alberts SR, Chowhan NM, Shpilsky A, Hochster HS (2008). Intermittent oxaliplatin administration and time-to-treatment failure in metastatic colorectal cancer: final results of the phase III CONcePT trial. Proc ASCO Annual Meeting, abstract 4010","DOI":"10.1200\/jco.2008.26.15_suppl.4010"},{"key":"740_CR19","doi-asserted-by":"crossref","unstructured":"Cassidy J, Bjarnason GA, Hickish T, Topham C, Provencio M, Bodkoky G, Landherr L, Koralewski P, Lopez-Vivanco G, Said G (2006) Randomized double blind placebo controlled phase III study assessing the efficacy of xaliproden in reducing the cumulative peripheral sensory neuropathy induced by the oxaliplatin and 5-FU\/LV combination (FOLFOX4) in first line treatment of patients with metastatic colorectal cancer. Proc ASCO Gastrointestinal Cancers Symposium, abstract 229","DOI":"10.1200\/jco.2006.24.18_suppl.3507"},{"key":"740_CR20","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1634\/theoncologist.12-3-312","volume":"12","author":"WS Wang","year":"2007","unstructured":"Wang WS, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Chiou TJ, Liu JH, Yen CC, Chen PM (2007) Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. The Oncologist 12:312\u2013319","journal-title":"The Oncologist"},{"key":"740_CR21","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s00520-006-0018-9","volume":"14","author":"PC Lin","year":"2006","unstructured":"Lin PC, Lee MY, Wang WS, Yen CC, Chao TC, Hsiao LT, Yang MH, Chen PM, Lin KP, Chiou TJ (2006) N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data. Support Care Cancer 14:484\u2013487","journal-title":"Support Care Cancer"},{"key":"740_CR22","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1200\/JCO.2002.07.061","volume":"15","author":"S Cascinu","year":"2002","unstructured":"Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, Beretta GD, Ubiali E, Catalano G (2002) Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 15:3478\u20133483","journal-title":"J Clin Oncol"},{"key":"740_CR23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1085-9489.2006.00078.x","volume":"11","author":"G Cavaletti","year":"2006","unstructured":"Cavaletti G, Jann S, Pace A, Plasmati R, Siciliano G, Briani C, Cocito D, Padua L, Ghiglione E, Manicone M, Giussani G (2006) Multi-cener assessment of the total neuropathy score for chemotherapy-induced peripheral neuropathy. J Peripher Nerv Syst 11:135\u2013141","journal-title":"J Peripher Nerv Syst"},{"key":"740_CR24","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A","year":"2004","unstructured":"Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A (2004) Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343\u20132351","journal-title":"N Engl J Med"},{"key":"740_CR25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1023\/A:1026458604826","volume":"6","author":"RJ Stephens","year":"1997","unstructured":"Stephens RJ, Hopwood P, Girling DJ, Machin D (1997) Randomized trials with quality of life endpoints: are doctors\u2019 ratings of patients\u2019 physical symptoms interchangeable with patients\u2019 self ratings? Qual Life Res 6:225\u2013236","journal-title":"Qual Life Res"},{"key":"740_CR26","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00520-005-0868-6","volume":"14","author":"AA Argyriou","year":"2006","unstructured":"Argyriou AA, Polychronopoulos P, Koutras A, Iconomou G, Gourzis P, Assimakopoulos K, Kalofonos HP, Chroni E (2006) Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy? Support Care Cancer 14:223\u2013229","journal-title":"Support Care Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-009-0740-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-009-0740-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-009-0740-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T03:44:26Z","timestamp":1590119066000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-009-0740-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,12]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["740"],"URL":"https:\/\/doi.org\/10.1007\/s00520-009-0740-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,12]]}}}